Some reviews note miRNAs modulate chemoresistance (e.g., affecting autophagy, apoptosis) and immune checkpoints in cancer [80,85], but validated HCC-specific biomarkers for cisplatin/doxorubicin or PD-1/PD-L1 therapies have not yet emerged. This evidence concerns the gene CD274 and cancer.